Navigation Links
HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
Date:4/8/2008

COLORADO SPRINGS, Colo., April 8, 2008 /PRNewswire/ -- HemoGenix(R), Inc., a privately-held contract research and assay development company, reported that the USPTO has issued the first two of several patent applications for the company's HALO(R) technology. HALO(R) is the 21st century answer and the only alternative to, and replacement for, the traditional colony-forming cell (CFC) assay, first described in 1966.

HALO(R) was developed and validated by HemoGenix(R) with the help of a SBIR Phase I and II grant from the National Cancer Institute (NCI). Development began in January 2001. The HALO(R) Platform for in vitro hemotoxicity testing of new drug candidates being developed by biotechnology and pharmaceutical companies was launched at the Society of Toxicology meeting in March 2001. Since that time, HemoGenix(R) has developed 3 versions of its HALO(R) Platform, each designed for specific applications.

The HALO(R) Research Platform is for basic research scientists in academia and other research institutions. The HALO(R) Stem and Progenitor Cell -- Quality Control (SPC-QC) and HALO(R)-96 PQR (Potency, Quality Release) Platforms were designed for stem cell transplantation and cord blood bank processing laboratories to address the requirement for "appropriate" and "validated" assays for umbilical cord blood stem cell products prior to transplantation into patients. Finally, the HALO(R) Predictive Hemotoxicity Platform was designed for all stages of drug development from early high-throughput screening to pre-clinical studies and patient monitoring during clinical trials. The HALO(R) Hemotoxicity Platform provides easy to use, robust, reliable and validated predictive tools to detect potential toxic side effects to stem cells of the blood-forming (hematopoietic) system for drug development and environmental agent testing.

All HALO(R) platforms rely on highly sensitive and fully standardized, instrument-based, ATP bioluminescence technology. This innovative technology has allowed HemoGenix(R) to become "The Leader in Hemotoxicity Testing."

Instrumental in the issuance of the patents by the USPTO were David Rosenbaum and Donna Becker of Rosenbaum & Associates, P.C. of Northbrook, IL. "If it was not for David's interest and belief in HemoGenix and Donna's exuberance in learning and obtaining a thorough understanding of our work and products and her persistence and communication with the USPTO, we would certainly not be in this position today," said Ivan Rich, Ph.D., Founder and CEO of HemoGenix(R). "For a small, but growing company like HemoGenix(R), IP is of fundamental importance to us, not only as validation for what we do, but also for future business, market share and strategic partnerships. This is an important milestone for us. I am extremely grateful to David Rosenbaum and Donna Becker for all the help, assistance and trust they have given us and continue to give us."

About HemoGenix(R), Inc.

HemoGenix(R) Inc., a privately-held contract research and assay development company was started in 2000 in South Carolina and relocated to Colorado Springs, Colorado in 2003. HemoGenix has developed its own portfolio of proprietary and now patented in vitro assay platforms for basic research, stem cell quality control, potency and release assays for stem cell transplantation processing laboratories and toxicity, safety and risk assessment for drug development and environmental testing. HemoGenix(R) develops and validates its in vitro assays first for its contract services and then as assay kits for in house use that are sold directly or through its distributors worldwide.

About Rosenbaum & Associates, P.C.

Rosenbaum & Associates, P.C., located in Northbrook, IL, is a full spectrum intellectual property law firm providing services for the life sciences community. The firm specializes in meeting the needs of start-up and emerging companies and has successfully worked with individual inventors, university faculty members and entrepreneurs during the entire corporate life-cycle. The firm is committed to providing business-oriented intellectual property legal services in a prompt, courteous and professional manner.

CONTACT:

Ivan N. Rich, Ph.D.

Founder & CEO

719-264-6250


'/>"/>
SOURCE HemoGenix(R), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
2. SemBioSys receives milestone payments from AVAC Ltd.
3. Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative
4. EntreMed Receives Nasdaq Deficiency Notice
5. Memory Pharmaceuticals Receives Nasdaq Notification
6. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Pharmasset Receives $10 Million of Working Capital
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Lajollacooks4u has become ... has consistently been rated one of its top attractions. Fortune 500 companies, such ... participate in a unique and intimate team-building experience. , Each event kicks off with ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety of ... could lead to one good one. Surviving Mesothelioma has just posted an article on ... evaluated 98 mesothelioma patients who got a second kind of drug therapy ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ., ... artificial intelligence, real-time decision support tools in the emergency room, ... the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology Week, ... David Intercontinental Hotel in Tel Aviv, Israel ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016  FlexTech, ... in the categories of Innovation, Research & Development, Leadership ... Industry Leadership. This is the 9 th year ... select group of companies and individuals from past ... nominations based on a pre-described set of criteria, by ...
Breaking Biology News(10 mins):